Identification of Novel Clinical Factors Associated with Hepatic Fat Accumulation in Extreme Obesity

Table 3

Multiple regression results for severity of hepatic fat (grades 2 and 3 versus grade 1).

	Odds ratio	95% confidence interval	value
Glucose level
<100 mg/dL	Reference
100–124 mg/dL	1.475	1.161, 1.876	0.0015
125–199 mg/dL	1.655	1.231, 2.225	0.0009
200+ mg/dL	2.530	1.632, 3.922	<0.0001
Serum insulin > 17 µU/mL	1.900	1.532, 2.357	<0.0001
Triglyceride level
<125 mg/dL	Reference
125–199 mg/dL	1.415	1.126, 1.778	0.0029
200+ mg/dL	1.448	1.117, 1.877	0.0052
ALT level
Quartile 1 (<20 U/L)	Reference
Quartile 2: (20–25 U/L)	1.690	1.247, 2.290	0.0007
Quartile 3: (26–36 U/L)	2.765	2.065, 3.703	<0.0001
Quartile 4: (37+ U/L)	5.144	3.616, 7.319	<0.0001
AST level
Quartile 1, 2, or 3 (<31 U/L)	Reference
Quartile 4 (31+ U/L)	1.696	1.288, 2.235	0.0002
BUN level
Quartile 1 (<13 mg/dL)	1.556	1.264, 1.917	<0.0001
Quartile 2, 3, or 4 (13+ mg/dL)	Reference
Use of metformin	1.432	1.175, 1.745	0.0004
Use of fibric acid derivative	1.766	1.188, 2.626	0.0050
Use of tricyclics or modified cyclics	1.488	1.099, 2.013	0.0101
Female gender	1.295	1.017, 1.649	0.0359
Pre-op weight change
Weight gain	3.325	2.288, 4.834	<0.0001
0–4 %EWL	2.636	1.793, 3.876	<0.0001
5–9 %EWL	2.436	1.703, 3.484	<0.0001
10–19 %EWL	1.561	1.115, 2.185	0.0094
20+ %EWL	Reference

c-statistic = 0.772.